$RAPT News
Last published 9mo ago
- 9mo agoGSKRAPTForbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSKGlobeNewswireNAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE:GSK) has entered into a definitive agreement
- 10mo agoRAPTRAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent HighlightsGlobeNewswire- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had
- 1y agoRAPTRAPT Therapeutics to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food AllergiesGlobeNewswireTrial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with
- 1y agoRAPTRAPT Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and
- 1y agoRAPTRAPT Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and
- 1y agoRAPTRAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous UrticariaGlobeNewswire- RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing- Efficacy sustained at Week 16 after a single dose of RPT904- Well tolerated with no serious adverse events
- 1y agoRAPTRAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food AllergyGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.
- 1y agoRAPTRAPT Therapeutics to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering,
- 1y agoRAPTRAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) (the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and
- 1y agoRAPTRAPT Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Reports First Quarter 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering,
- 1y agoRAPTRAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical DevelopmentGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company") is a clinical-stage immunology-based biopharmaceutical company focused on discovering,
- 1y agoRAPTRAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoCTNMRAPTRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 1y agoRAPTRAPT Therapeutics Announces $150 Million Private PlacementGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel
- 1y agoRAPTRAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyGlobeNewswire- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - -
- 1y agoRAPTRAPT Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTBased on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 2y agoRAPTRAPT Therapeutics Reports Second Quarter 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics Reports First Quarter 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsGlobeNewswire- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients
- 2y agoRAPTRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTInvestigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLCGlobeNewswireATLANTA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. ("RAPT Therapeutics," or the "Company") (NASDAQ:RAPT) complied with federal securities laws. On
- 2y agoRAPTRAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonGlobeNewswire- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company
- 2y agoRAPTRAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 2y agoRAPTRAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyGlobeNewswirePositive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeksFurther deepening of response
- 2y agoRAPTRAPT Therapeutics Reports Third Quarter 2023 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCGlobeNewswire- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at
- 3y agoRAPTRAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics to Participate in Several Upcoming Investor Conferences in SeptemberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics Reports Second Quarter 2023 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced CancersGlobeNewswire-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1
- 3y agoRAPTRAPT Therapeutics Reports First Quarter 2023 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics Announces the Appointment of Michael Listgarten as General CounselGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe AsthmaGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTInvestigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLCGlobeNewswireATLANTA, March 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. ("RAPT Therapeutics," or the "Company") (NASDAQ:RAPT) complied with federal securities laws. On
- 3y agoRAPTRAPT Therapeutics Reports Fourth Quarter And Year End Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral
- 3y agoRAPTRAPT Therapeutics to Participate in the SVB Securities Global Biopharma ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing
- 3y agoRAPTRAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing